 City broker Shore Capital remained upbeat on the prospects for shares in GSK PLC LSE:GSK, NYSE:GSK in spite of the failure of a key clinical trial for a new bone marrow cancer drug. It repeated its buy recommendation and said stock in the pharma giant was materially undervalued compared with its peers. 